CONCORDBIO vs GLAXO: Stock Comparison
GLAXOSMITHKLINE PHARMA LT is the larger company by market capitalisation. GLAXOSMITHKLINE PHARMA LT shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CONCORDBIO leads 1; GLAXO leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CONCORDBIO | GLAXO |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | CONCORDBIO | GLAXO |
|---|---|---|
| Live Price | ₹1,233.8 | ₹2,507.7 |
| Day Change | 0.26% | -0.29% |
| Volume | 14,797 | 815 |
| 52-Week High | ₹1,615 | ₹3,120.7 |
| 52-Week Low | ₹987 | ₹2,088.1 |
| Distance from 52W High | -23.6% | -19.64% |
Valuation
| Metric | CONCORDBIO | GLAXO |
|---|---|---|
| Market Cap | ₹12,847 Cr | ₹42,795 Cr |
| P/E Ratio | 45.59x | 39.89x |
| P/B Ratio | 6.2x | 18.79x |
| EPS | ₹26.71 | ₹63.05 |
| Book Value | ₹195.37 | ₹133.85 |
| Dividend Yield | 0.6% | 2.28% |
Growth
| Metric | CONCORDBIO | GLAXO |
|---|---|---|
| Revenue Growth (TTM YoY) | -24.1% | 2.1% |
| EPS Growth (TTM YoY) | -37% | 5.7% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | CONCORDBIO | GLAXO |
|---|---|---|
| ROE | 13.03% | 45.34% |
| ROCE | 13.09% | 87.77% |
| Net Margin | 24.6% | 27.29% |
| Operating Margin | 33.33% | 36.86% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | CONCORDBIO | GLAXO |
|---|---|---|
| Promoter Holding | 44.09%▲ 0.01 pp | 75% |
| FII Holding | 7.28%▼ 0.24 pp | 4.75%▼ 0.04 pp |
| DII Holding | 10.95%▲ 1.59 pp | 8.48%▲ 0.68 pp |
| Public Holding | 37.68%▼ 1.35 pp | 11.77%▼ 0.64 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CONCORD BIOTECH and GLAXOSMITHKLINE PHARMA LT.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.